Anti-inflammatory Therapy for Sarcoidosis

Clin Chest Med. 2024 Mar;45(1):131-157. doi: 10.1016/j.ccm.2023.08.010. Epub 2023 Sep 9.

Abstract

Over 50% of patients with sarcoidosis will require anti-inflammatory therapy at some point in their disease course. Indications for therapy are to improve health-related quality of life, prevent or arrest organ dysfunction (or organ failure) or avoid death. Recently published treatment guidelines recommended a stepwise approach to therapy however there are some patients for whom up front combination or more intense therapy maybe reasonable. The last decade has seen an explosion of studies and trials evaluating novel therapeutic agents and treatment strategies. Currently available anti-inflammatory therapies and several novel therapies are discussed here.

Keywords: Anti-TNF agents; Anti-inflammatory; Biologics; Efzofitimod; Glucocorticoids; HRQoL; Infliximab; Stepwise treatment.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal* / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Quality of Life
  • Sarcoidosis* / drug therapy
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Infliximab
  • Anti-Inflammatory Agents
  • Tumor Necrosis Factor-alpha